Chloroquine inhibits lytic replication of Kaposi's sarcoma-associated herpesvirus by disrupting mTOR and p38-MAPK activation

Antiviral Research

Volumn 133, Issue , 2016, Pages 223-233

  Yang, Mengtian ^a   Huang, Lu ^a   Li, Xiaojuan ^a   Kuang, Ersheng ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chloroquine; Kaposi's sarcoma associated herpesvirus; Lytic replication; mTOR; p38 MAPK

Indexed keywords

CHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; ANTIVIRUS AGENT; TARGET OF RAPAMYCIN KINASE;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; LYSIS; MALARIA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; VIRION; VIRUS GENE; VIRUS REPLICATION; CELL LINE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; B-LYMPHOCYTES; CELL LINE; CHLOROQUINE; ENZYME ACTIVATION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TOR SERINE-THREONINE KINASES; VIRUS REPLICATION;

EID: 84983605929     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.08.010     Document Type: Article

References (48)

1. Bhatt, A.P., Damania, B., AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV. Front. Immunol., 3, 2012, 401.
2. Boshoff, C., Chang, Y., Kaposi's sarcoma-associated herpesvirus: a new DNA tumor virus. Annu. Rev. Med. 52 (2001), 453–470.
3. Boshoff, C., Schulz, T.F., Kennedy, M.M., Graham, A.K., Fisher, C., Thomas, A., McGee, J.O., Weiss, R.A., O'Leary, J.J., Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat. Med. 1 (1995), 1274–1278.
4. Chang, H.H., Ganem, D., A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell host microbe 13 (2013), 429–440.
5. Ciufo, D.M., Cannon, J.S., Poole, L.J., Wu, F.Y., Murray, P., Ambinder, R.F., Hayward, G.S., Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J. Virol. 75 (2001), 5614–5626.
6. Cohen, A., Brodie, C., Sarid, R., An essential role of ERK signalling in TPA-induced reactivation of Kaposi's sarcoma-associated herpesvirus. J. general Virol. 87 (2006), 795–802.
7. Dupin, N., Fisher, C., Kellam, P., Ariad, S., Tulliez, M., Franck, N., van Marck, E., Salmon, D., Gorin, I., Escande, J.P., Weiss, R.A., Alitalo, K., Boshoff, C., Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 4546–4551.
8. Duran, A., Amanchy, R., Linares, J.F., Joshi, J., Abu-Baker, S., Porollo, A., Hansen, M., Moscat, J., Diaz-Meco, M.T., p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol. cell 44 (2011), 134–146.
9. Freiberg, A.N., Worthy, M.N., Lee, B., Holbrook, M.R., Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J. general Virol. 91 (2010), 765–772.
10. Ganem, D., KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu. Rev. Pathol. 1 (2006), 273–296.
11. Ganem, D., KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J. Clin. Investig. 120 (2010), 939–949.
12. Granato, M., Santarelli, R., Farina, A., Gonnella, R., Lotti, L.V., Faggioni, A., Cirone, M., Epstein-barr virus blocks the autophagic flux and appropriates the autophagic machinery to enhance viral replication. J. Virol. 88 (2014), 12715–12726.
13. Grundhoff, A., Ganem, D., Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J. Clin. Investig. 113 (2004), 124–136.
14. Haque, A., Rachinel, N., Quddus, M.R., Haque, S., Kasper, L.H., Usherwood, E., Co-infection of malaria and gamma-herpesvirus: exacerbated lung inflammation or cross-protection depends on the stage of viral infection. Clin. Exp. Immunol. 138 (2004), 396–404.
15. Homewood, C.A., Warhurst, D.C., Peters, W., Baggaley, V.C., Lysosomes, pH and the anti-malarial action of chloroquine. Nature 235 (1972), 50–52.
16. Kikuta, H., Itakura, O., Taneichi, K., Kohno, M., Tropism of human herpesvirus 8 for peripheral blood lymphocytes in patients with Castleman's disease. Br. J. Haematol. 99 (1997), 790–793.
17. Kimura, T., Takabatake, Y., Takahashi, A., Isaka, Y., Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 73 (2013), 3–7.
18. Kono, M., Tatsumi, K., Imai, A.M., Saito, K., Kuriyama, T., Shirasawa, H., Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antivir. Res. 77 (2008), 150–152.
19. Kuang, E., Fu, B., Liang, Q., Myoung, J., Zhu, F., Phosphorylation of eukaryotic translation initiation factor 4B (EIF4B) by open reading frame 45/p90 ribosomal S6 kinase (ORF45/RSK) signaling axis facilitates protein translation during Kaposi sarcoma-associated herpesvirus (KSHV) lytic replication. J. Biol. Chem. 286 (2011), 41171–41182.
20. Kuang, E., Tang, Q., Maul, G.G., Zhu, F., Activation of p90 ribosomal S6 kinase by ORF45 of Kaposi's sarcoma-associated herpesvirus and its role in viral lytic replication. J. Virol. 82 (2008), 1838–1850.
21. Lambert, P.J., Shahrier, A.Z., Whitman, A.G., Dyson, O.F., Reber, A.J., McCubrey, J.A., Akula, S.M., Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis. Expert Opin. Ther. targets 11 (2007), 589–599.
22. Lenoir, G., Geser, A., Effect of chloroquine on Epstein-Barr virus expression. Nature, 282, 1979, 758.
23. Li, M., Khambu, B., Zhang, H., Kang, J.H., Chen, X., Chen, D., Vollmer, L., Liu, P.Q., Vogt, A., Yin, X.M., Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. J. Biol. Chem. 288 (2013), 35769–35780.
24. Li, X., Du, S., Avey, D., Li, Y., Zhu, F., Kuang, E., ORF45-Mediated prolonged c-Fos accumulation accelerates viral transcription during the late stage of lytic replication of Kaposi's sarcoma-associated herpesvirus. J. Virol. 89 (2015), 6895–6906.
25. Madrid, P.B., Chopra, S., Manger, I.D., Gilfillan, L., Keepers, T.R., Shurtleff, A.C., Green, C.E., Iyer, L.V., Dilks, H.H., Davey, R.A., Kolokoltsov, A.A., Carrion, R. Jr., Patterson, J.L., Bavari, S., Panchal, R.G., Warren, T.K., Wells, J.B., Moos, W.H., Burke, R.L., Tanga, M.J., A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PloS one, 8, 2013, e60579.
26. Manic, G., Obrist, F., Kroemer, G., Vitale, I., Galluzzi, L., Chloroquine and hydroxychloroquine for cancer therapy. Mol. Cell. Oncol., 1, 2014, e29911.
27. Martin, J.N., The epidemiology of KSHV and its association with malignant disease. Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., (eds.) Human Herpesviruses, 2007, Biology, Therapy, and Immunoprophylaxis, Cambridge.
28. Martinez-Lopez, N., Athonvarangkul, D., Mishall, P., Sahu, S., Singh, R., Autophagy proteins regulate ERK phosphorylation. Nat. Commun., 4, 2013, 2799.
29. Matar, C.G., Anthony, N.R., O'Flaherty, B.M., Jacobs, N.T., Priyamvada, L., Engwerda, C.R., Speck, S.H., Lamb, T.J., Gammaherpesvirus Co-infection with malaria suppresses anti-parasitic humoral immunity. PLoS Pathog., 11, 2015, e1004858.
30. Mizushima, N., Yoshimori, T., Levine, B., Methods in mammalian autophagy research. Cell 140 (2010), 313–326.
31. Myoung, J., Ganem, D., Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J. Virol. methods 174 (2011), 12–21.
32. Nalwoga, A., Cose, S., Wakeham, K., Miley, W., Ndibazza, J., Drakeley, C., Elliott, A., Whitby, D., Newton, R., Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Trop. Med. Int. health TM IH 20 (2015), 665–672.
33. Nascimento, M.C., Malaria may influence the transmission of Kaposi sarcoma associated herpesvirus in endemic areas. Jaids-J Acq Imm Def. 67 (2014), E41–E43.
34. Nichols, L.A., Adang, L.A., Kedes, D.H., Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PloS one, 6, 2011, e14535.
35. Pallister, J., Middleton, D., Crameri, G., Yamada, M., Klein, R., Hancock, T.J., Foord, A., Shiell, B., Michalski, W., Broder, C.C., Wang, L.F., Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J. Virol. 83 (2009), 11979–11982.
36. Pascolo, S., Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. Eur. J. Pharmacol. 771 (2016), 139–144.
37. Rolain, J.M., Colson, P., Raoult, D., Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int. J. Antimicrob. Agents 30 (2007), 297–308.
38. Ruocco, E., Ruocco, V., Tornesello, M.L., Gambardella, A., Wolf, R., Buonaguro, F.M., Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin. Dermatol. 31 (2013), 413–422.
39. Ruocco, V., Ruocco, E., Schwartz, R.A., Janniger, C.K., Kaposi sarcoma and quinine: a potentially overlooked triggering factor in millions of Africans. J. Am. Acad. Dermatol. 64 (2011), 434–436.
40. Savarino, A., Use of chloroquine in viral diseases. Lancet Infect. Dis. 11 (2011), 653–654.
41. Savarino, A., Boelaert, J.R., Cassone, A., Majori, G., Cauda, R., Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect. Dis. 3 (2003), 722–727.
42. Savarino, A., Di Trani, L., Donatelli, I., Cauda, R., Cassone, A., New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 6 (2006), 67–69.
43. Sharma-Walia, N., Krishnan, H.H., Naranatt, P.P., Zeng, L., Smith, M.S., Chandran, B., ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J. Virol. 79 (2005), 10308–10329.
44. Siakallis, G., Spandidos, D.A., Sourvinos, G., Herpesviridae and novel inhibitors. Antivir. Ther. 14 (2009), 1051–1064.
45. Skorenski, M., Sienczyk, M., Anti-herpesvirus agents: a patent and literature review (2003 to present). Expert Opin. Ther. Pat. 24 (2014), 925–941.
46. Srivastava, V., Lee, H., Chloroquine-based hybrid molecules as promising novel chemotherapeutic agents. Eur. J. Pharmacol. 762 (2015), 472–486.
47. Wakeham, K., Webb, E.L., Sebina, I., Muhangi, L., Miley, W., Johnson, W.T., Ndibazza, J., Elliott, A.M., Whitby, D., Newton, R., Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women. Infect. agents cancer, 6, 2011, 15.
48. Weber, S.M., Chen, J.M., Levitz, S.M., Inhibition of mitogen-activated protein kinase signaling by chloroquine. J. Immunol. 168 (2002), 5303–5309.